Trials / Terminated
TerminatedNCT04475549
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Tisento Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
Detailed description
IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IW-6463 Tablets | IW-6463 tablets administered orally (daily) |
Timeline
- Start date
- 2020-11-13
- Primary completion
- 2022-01-23
- Completion
- 2022-01-23
- First posted
- 2020-07-17
- Last updated
- 2024-08-29
- Results posted
- 2023-11-15
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04475549. Inclusion in this directory is not an endorsement.